中文摘要：

目的探讨血清白细胞介素-6在神经胶质瘤患者预后中的潜在意义。方法收集手术前182位神经胶质瘤病人和49位正常供血者的血清样本。使用酶联免疫吸附试验测定白细胞介素-6水平。与血清癌胚抗原（CEA）、甲胎球蛋白（AFP）和C-反应蛋白（CRP）水平比较,评估白介素-6的临床意义。结果神经胶质瘤患者血清白介素-6水平明显高于健康对照组。血清白介素-6水平与癌胚抗原密切相关,但是与AFP和CRP关系不大。患者血清IL-6水平与患者TNM分期显著相关。此外,高血清的IL-6水平与神经胶质瘤的不良预后相关联。结论血清IL-6是神经胶质瘤的预后因子。

英文摘要：

Objective To study the prognosis significance of interleukin-6 （IL-6） level in serum of glioma patients.Methods Preoperative serum samples from 182 patients with glioma and 49 normal healthy volunteers were used to determine IL-6 levels by enzyme-linked immunosorbent assay （ELISA）.The clinical significance of serum IL-6 levels was evaluated and compared with serum carcinoembryonic antigen （CEA） levels,alpha-fetoglobulin （AFP） and serum C-reactive protein （CRP） levels in these patients.Results The serum level of IL-6 was significantly higher in glioma patients than in healthy subjects,and strongly correlated with CEA levels,but not with AFP or CRP levels.Strong positive correlations were observed between serum IL-6 levels and tumor TNM stage.Furthermore,high serum IL-6 levels were associated with a worse prognosis in the glioma patients.Conclusion Serum IL-6 may be a prognosis factor for glioma progression.